Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$644.37M-160%-$453.82M-113%-$364.89M-87.5%-$305.21M-95.3%-$247.79M-86.0%
$2.45M+6.8%$2.35M+38.7%$2.27M+30.7%$1.53M-4.4%$2.29M+43.3%
$67M+132%$87.3M+248%$33.7M+50.2%$30.78M+48.2%$28.83M+45.8%
-$387.32M-74.7%-$354.17M-82.2%-$274.24M-98.3%-$207.31M-59.0%-$221.76M-73.0%
$2.29M-69.3%$1.54M-52.9%$1.93M+57.5%$3.35M-4.9%$7.45M+211%
-$1.66B-4,939%$172.62M+1,182%$74.88M+119%$24.85M+216%$34.28M—
$2.42B+843%$238.74M+27,216%$365.66M-58.2%$0-100%$256.58M+3,319%
$374.5M—$57.19M+127%——-$184.05M-147%——
-$389.61M-70.0%-$355.7M-79.9%-$276.16M-97.9%-$210.66M-57.3%-$229.21M-75.5%

FAQ

How much cash does Revolution Medicines, Inc. generate?
Revolution Medicines, Inc. (RVMD) generated -$1.2B in operating cash flow over the trailing twelve months.
What is Revolution Medicines, Inc.'s free cash flow?
After $9.1M of capital expenditures, Revolution Medicines, Inc.'s free cash flow was -$1.2B over the trailing twelve months, down 75.9% year over year.
Where does Revolution Medicines, Inc.'s cash flow data come from?
Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.